Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection of M-protein by iMS-IP and iMS-FLC assays redefines previously non-secretory POEMS syndrome.

Clinical chemistry and laboratory medicine·2026
Same author

Attenuated prognostic discrimination among Mayo stages I-IIIa and improved survival in stage IIIb in the daratumumab era: a real-world study of newly diagnosed AL amyloidosis.

Leukemia & lymphoma·2026
Same author

Methionine, Homocysteine, and Methylation Levels Predict Cognitive Decline in Alzheimer's Disease.

CNS neuroscience & therapeutics·2026
Same author

Hepatic Response Dynamics in Newly Diagnosed Patients with Light-chain Amyloidosis: A Retrospective Cohort Study.

Advances in therapy·2026
Same author

Stage-specific neurotoxicity of lead in zebrafish: Metabolic disruption in embryos and ferroptosis in larvae.

Journal of hazardous materials·2025
Same author

Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis.

Annals of hematology·2025

Related Experiment Video

Updated: Jun 18, 2026

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.

Xinyue Zhao1, Chenyu Wang2, Yuping Ge2

  • 1Department of Health Care, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Anti-Cancer Drugs
|June 17, 2026
PubMed
Summary

A patient with advanced primary splenic angiosarcoma (PSA) and a PIK3CA mutation showed rapid improvement with inavolisib and lenvatinib. This combination therapy offers a promising new option for refractory angiosarcoma.

Keywords:
case reportinavolisiblenvatinibprimary splenic angiosarcomatargeted therapy

Related Experiment Videos

Last Updated: Jun 18, 2026

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Area of Science:

  • Oncology
  • Genetics
  • Vascular Biology

Background:

  • Primary splenic angiosarcoma (PSA) is a rare and aggressive vascular cancer with limited treatment options and poor prognosis.
  • Metastatic PSA presents significant challenges, often leading to treatment resistance and complications like hepatic failure and thrombocytopenia.

Purpose of the Study:

  • To report the first use of inavolisib, a PI3Kα inhibitor, in combination with lenvatinib for treating refractory metastatic primary splenic angiosarcoma.
  • To evaluate the efficacy and safety of this novel combination therapy in a patient with a specific PIK3CA mutation.

Main Methods:

  • Genomic profiling of metastatic PSA identified a PIK3CA p.P471L missense mutation.
  • A patient received sequential treatments including paclitaxel, liposomal doxorubicin, eribulin, toripalimab, and lenvatinib, with limited success.
  • Treatment was switched to a combination regimen of inavolisib and lenvatinib.

Main Results:

  • The combination of inavolisib and lenvatinib led to rapid normalization of bilirubin levels and recovery of platelet counts within two weeks.
  • Follow-up MRI confirmed radiological stabilization of the disease.
  • The patient remains alive and on treatment 16 months postdiagnosis, demonstrating significant clinical benefit.

Conclusions:

  • This case demonstrates the potential efficacy of targeting the PI3K/AKT/mTOR pathway in PIK3CA-mutated angiosarcoma.
  • Combined phosphoinositide 3-kinase and vascular endothelial growth factor pathway inhibition shows promise for refractory angiosarcoma.
  • Early genomic profiling is crucial for identifying actionable mutations and guiding personalized treatment strategies in rare cancers like PSA.